Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are known to impact the functional receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The association between chronic therapy with these medications and infection risk remains unclear.

Matéria Original


Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection


Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies